$4.24+0.09 (+2.17%)
OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, sells, and distributes diagnostic products and specimen collection devices in the United States, Europe, Africa, and internationally.
OraSure Technologies, Inc. in the Healthcare sector is trading at $4.24. Wall Street consensus targets $4.75 (2 analysts), implying a +12.0% move over the next 12 months. The stock is currently near its 52-week high of $4.33, remaining 43.7% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, sells, and distributes diagnostic products and specimen collection devices in the United States, Europe, Africa, and internationally. It offers OraQuick Rapi...
Global health emergencies are shifting sovereign biodefense strategies toward decentralized diagnostic networks capable of deploying rapid stockpiles.
Over the last 7 days, the U.S. market has dropped by 1.0%, yet it has risen by 23% over the past year, with earnings forecasted to grow annually by 17%. In such a fluctuating market, identifying stocks with strong fundamentals and growth potential is crucial for investors seeking stability and opportunity. While "penny stocks" may sound like an outdated term, they continue to represent smaller or less-established companies that can offer significant value; we've identified three such stocks...
Investors who take an interest in OraSure Technologies, Inc. ( NASDAQ:OSUR ) should definitely note that the...
Moby summary of OraSure Technologies, Inc.'s Q1 2026 earnings call
OraSure Technologies (NASDAQ:OSUR) reported first-quarter 2026 revenue of $27.9 million, topping the midpoint of its prior guidance range, as the company pointed to improving gross margins, ongoing cost actions, and preparations for two planned mid-year product launches that management expects to be